地西他滨对MDS患者JAK2基因表达的影响及临床意义

Influence of Decitabine on JAK2 expression in patients with MDS

目的:通过研究地西他滨对骨髓增生异常综合征(myelodysplastic syndrome,MDS)患者JAK2基因表达的影响进一步明确JAK2基因是否可作为预示地西他滨对MDS疗效的阳性分子标志物。方法:回顾2011年11月至2014年11月在门诊及住院确诊为骨髓增生异常综合征的患者共22例(其中高危MDS-RAEB型10例,低危MDS-RA型12例),抽取同期健康体检者20例作为对照组,应用FQ-PCR方法监测正常人群、MDS-RA型患者、MDS-RAEB型患者化疗前、MDS-RAEB型患者单药地西他滨化疗2周期及4周期后外周血JAK2-V617F实时定量PCR拷贝数。结果:MDS-RAEB型患者经地西他滨单药化疗2周期后外周血JAK2-V617F基因实时定量PCR拷贝数由化疗前的22545.98±11084.17下降为14654.88±7205.41,两组治疗前后比较差异有统计学意义(P<0.01)。再经地西他滨单药化疗4周期后JAK2-V617F基因PCR拷贝数与化疗2周期后比,由14654.88±7205.41下降为9469.31±4655.56,比较差异有统计学意义(P<0.0l)。结论:地西他滨可降低MDS-RAEB患者中JAK2-V617F基因的表达,并且增加地西他滨化疗周期可使JAK2-V617F基因表达进一步降低。

Objective： To study the effect of decitabine on JAK2 expression in MDS patients. Methods： To review the data of 22 patients diagnosed with myelodysplastic syndrome and 20 cases of normal control. FQ-PCR method was applied to test the peripheral blood JAK2-V617 F expression. Results： The peripheral blood JAK2-V617 F gene real time quantitative PCR copy number of patients with MDS-RAEB reduced from 22545. 98 ± 11084. 17 to 14654. 88± 7205. 41 after 2 cycles of chemotherapy by decitabine single-agent chemotherapy. The two groups before and after treatment difference was statistically significant（ P〈0. 01）. The peripheral blood JAK2-V617 F gene real time quantitative PCR copy number reduced from 14654. 88 ± 7205. 41 to 9469. 31 ± 4655. 56 after two more cycles of chemotherapy by decitabine single-agent chemotherapy. difference was statistically significant（ P〈0. 0 l）. Conclusion：Decitabine can reduce JAK2 V617 F gene expression significantly in patients with MDS RAEB.